Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTavistock Regulatory News (TAVI)

Share Price Information for Tavistock (TAVI)

Share Price is delayed by 15 minutes
Get Live Data
3.15    0.00 (0.00%)
Bid:
3.00
Ask:
3.30
Spread: 0.30 (10.00%)
Market Cap: £13.89m
TAVI Live PriceLast checked at - London Stock Exchange

Intraday Tavistock Share Chart

Trading Update And Entry Into Loan Facility

27 Sep 2019 07:00

RNS Number : 8763N
Tavistock Investments PLC
27 September 2019
 

Tavistock Investments Plc

("Tavistock" or the "Company")

Ticker: TAVI

TRADING UPDATE AND ENTRY INTO LOAN FACILITY

 

27  September 2019

 

Trading update

The Board is pleased to report that the Company is trading in line with market expectations, despite challenging market conditions caused by political instability, anxieties over BREXIT outcomes and international trade disputes.

It is impossible to determine how much more challenging conditions may become over the short term and any potential impact on the Company's future trading before more normal conditions return.

The Board continues to believe that it is in the best long-term interests of the Company to improve profitability through:

·; the selective purchases of client books from retiring advisers;

·; investment in initiatives designed to significantly improve inflows of FUM; and

·; reduction of net debt through scheduled capital repayments under its existing NatWest loan facility.

The Company's regulatory capital requirement has increased as a result of these initiatives. However, the Directors' believe that seeking to raise additional capital now would be unduly dilutive for shareholders. To bolster the regulatory capital position in a manner that is not dilutive to shareholders, they have entered into an unsecured convertible loan facility (the "Facility") with two of the Company's directors and its Chief Investment Officer.

The Facility

The Facility is for £630,000 and may be drawn down by the Company at any point within the next year. The Facility is unsecured and is being provided by two of the Company's directors, Oliver Cooke and Brian Raven, and by its Chief Investment Officer, Christopher Peel. Each of them has given an irrevocable undertaking to the Company that upon receipt of 30 days' notice and subject to compliance with regulatory obligations regarding close periods, they will provide up to £210,000 of loan capital to the Company on the following terms:

·; Facility fee 5% of the funds committed;

·; interest payable on funds drawn down of 10%;

·; the repayment of any sums drawn down, together with interest thereon, to be made on 30 September 2020;

·; the option for the Company only, at its absolute discretion, to elect to convert amounts drawn down, together with interest thereon, into new ordinary shares in the Company of 1p each, at a conversion price of 2p per share, being today's bid price; and

·; a non-utilisation fee payable, if appropriate, on 30 September 2020, equivalent to 3% of funds committed but not drawn down.

Related Party Transaction

The entry into the Facility by the Company with Oliver Cooke, Brian Raven and Christopher Peel constitute transactions with related parties under the AIM Rules for Companies. The independent Non-executive Directors of the Company, Roderic Rennison and Peter Dornan, having consulted with the Company's nominated Adviser, Arden Partners, consider that the terms of the transaction are fair and reasonable insofar as the Company's shareholders are concerned.

 

ENQUIRIES

Tavistock Investment plc

Oliver Cooke / Brian Raven +44 (0)1753 867000

Arden Partners plc - Nominated Adviser

Paul Shackleton +44 (0)20 7614 5900

Allenby Capital Limited - Broker

Nick Naylor / Nick Athanas +44 (0)20 3328 5656

Vested - PR Partner

Elspeth Rothwell +44 (0)20 3890 8118

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTSEDFUMFUSESU
Date   Source Headline
29th May 20269:00 amRNSDirectorate Change
2nd Apr 20267:00 amRNSCompletion of Acquisition
30th Mar 20262:55 pmRNSChange of Auditor
5th Feb 20267:00 amRNSFurther Update on Litigation with Titan
20th Jan 20267:00 amRNSAppointment of Nominated Adviser and Broker
23rd Dec 20257:00 amRNSInterim Results
23rd Dec 20257:00 amRNSInterim Results
17th Dec 202512:13 pmRNSFurther update re ongoing litigation with Titan
16th Dec 20257:00 amRNSUpdate re ongoing litigation with Titan
6th Nov 202512:00 pmRNSResult of AGM
2nd Oct 20257:00 amRNSUpdate re ongoing litigation
30th Sep 20255:00 pmRNSTotal Voting Rights
30th Sep 20257:00 amRNSNotice of AGM
25th Sep 20257:00 amRNSTransfer of Shares from treasury to EBT and TVR
24th Sep 202510:57 amRNSDirector/PDMR Shareholding
18th Sep 20257:00 amRNSFinal Results for the Year Ended 31 March 2025
15th Sep 20252:08 pmRNSHolding(s) in Company
11th Sep 20257:00 amRNSStrategic refocus and acquisition of Lifetime
7th Jul 202512:40 pmRNSDirector / PDMR Dealing
8th Apr 20254:15 pmRNSDirector/PDMR Shareholding
12th Mar 20257:00 amRNSTransaction in Own Shares
28th Feb 20255:00 pmRNSTotal Voting Rights
20th Feb 20257:00 amRNSCompletion of acquisition of Alpha Beta Partners
14th Feb 202512:08 pmRNSDirector/PDMR Shareholding
11th Feb 20257:00 amRNSTransaction in Own Shares,Director Dealing and TVR
6th Feb 20252:16 pmRNSDirector/PDMR Shareholding
30th Jan 202511:00 amRNSHolding(s) in Company
30th Jan 20259:53 amRNSHolding(s) in Company
6th Jan 202511:54 amRNSHolding(s) in Company
2nd Jan 20255:45 pmRNSTotal Voting Rights - Replacement
31st Dec 20241:30 pmRNSTotal Voting Rights
12th Dec 202412:00 pmRNSTransaction in Own Shares and Total Voting Rights
11th Dec 202411:30 amRNSResult of AGM
9th Dec 202412:49 pmRNSTransaction in Own Shares and Total Voting Rights
9th Dec 20247:00 amRNSInterim Results
2nd Dec 20247:00 amRNSRepositioning of Retail Asset Management business
22nd Nov 20247:00 amRNSStrategic acquisition and completion of disposal
11th Nov 20243:38 pmRNSNotice of AGM
30th Oct 202411:25 amRNSResult of General Meeting
2nd Oct 20243:50 pmRNSPublication of Circular and Notice of GM
2nd Oct 202411:32 amRNSDirector/PDMR Shareholding
1st Oct 20247:00 amRNSProposed disposals for up to £37.75 million
30th Sep 20247:00 amRNSFinal Results for the Year Ended 31 March 2024
19th Sep 20242:47 pmRNSUpdate on Titan Dispute
11th Jul 20247:00 amRNSFollow up to Titan termination announcement
8th Jul 20244:19 pmRNSTermination of strategic partnership
28th Jun 202410:16 amRNSStatement re press speculation
21st Jun 202410:31 amRNSDirectorate Change
31st May 20247:00 amRNSBoard role change
8th Jan 20247:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.